CanSino Biotech, an innovative biopharmaceutical company, completed its Star market IPO on 13 August.
The company had filed its application for the listing in January, in accordance with the fifth set of listing standards, which allows the listing of pre-revenue companies.
The proceeds of the IPO will be used for increasing new vaccine production capacity, and for R&D. CanSino was among the first companies to list in Hong Kong under the city bourse’s chapter 18A regime. Tian Yuan Law Firm acted as the legal adviser to CanSino in the Star market listing.